Baxter International Inc. (BAX) Holdings Raised by Bahl & Gaynor Inc.

Bahl & Gaynor Inc. boosted its position in shares of Baxter International Inc. (NYSE:BAX) by 24.8% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,940 shares of the medical instruments supplier’s stock after acquiring an additional 4,162 shares during the period. Bahl & Gaynor Inc.’s holdings in Baxter International were worth $928,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mirae Asset Global Investments Co. Ltd. bought a new stake in Baxter International during the 1st quarter worth approximately $365,000. Sivik Global Healthcare LLC bought a new stake in Baxter International during the 1st quarter worth approximately $5,705,000. Envestnet Asset Management Inc. raised its stake in Baxter International by 1.0% during the 1st quarter. Envestnet Asset Management Inc. now owns 268,759 shares of the medical instruments supplier’s stock worth $13,939,000 after acquiring an additional 2,564 shares during the period. Adalta Capital Management LLC bought a new stake in Baxter International during the 1st quarter worth approximately $1,207,000. Finally, Veritas Asset Management LLP raised its stake in Baxter International by 2.3% during the 2nd quarter. Veritas Asset Management LLP now owns 10,179,102 shares of the medical instruments supplier’s stock worth $616,243,000 after acquiring an additional 227,343 shares during the period. Institutional investors own 83.71% of the company’s stock.

In other Baxter International news, SVP Giuseppe Accogli sold 12,670 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was sold at an average price of $60.96, for a total value of $772,363.20. Following the completion of the sale, the senior vice president now directly owns 33,286 shares in the company, valued at approximately $2,029,114.56. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Carole J. Shapazian sold 4,020 shares of the company’s stock in a transaction on Thursday, August 24th. The shares were sold at an average price of $61.61, for a total value of $247,672.20. Following the completion of the sale, the director now owns 13,868 shares of the company’s stock, valued at $854,407.48. The disclosure for this sale can be found here. Over the last three months, insiders sold 35,050 shares of company stock valued at $2,158,587. 0.05% of the stock is owned by corporate insiders.

Baxter International Inc. (BAX) opened at 63.96 on Friday. The company has a 50 day moving average of $61.50 and a 200-day moving average of $57.69. The stock has a market capitalization of $34.85 billion, a price-to-earnings ratio of 38.81 and a beta of 0.66. Baxter International Inc. has a 12-month low of $43.13 and a 12-month high of $64.75.

Baxter International (NYSE:BAX) last posted its quarterly earnings data on Wednesday, July 26th. The medical instruments supplier reported $0.63 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.57 by $0.06. Baxter International had a return on equity of 14.82% and a net margin of 8.85%. The firm had revenue of $2.61 billion during the quarter, compared to the consensus estimate of $2.59 billion. During the same period in the prior year, the company earned $0.46 EPS. The firm’s revenue was up .8% compared to the same quarter last year. On average, equities research analysts forecast that Baxter International Inc. will post $2.39 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 2nd. Investors of record on Friday, September 1st will be paid a $0.16 dividend. This represents a $0.64 annualized dividend and a yield of 1.00%. The ex-dividend date is Wednesday, August 30th. Baxter International’s dividend payout ratio is currently 38.79%.

TRADEMARK VIOLATION NOTICE: This story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://ledgergazette.com/2017/09/17/baxter-international-inc-bax-holdings-raised-by-bahl-gaynor-inc.html.

BAX has been the topic of a number of recent analyst reports. Royal Bank Of Canada restated a “hold” rating and set a $60.00 target price on shares of Baxter International in a research note on Friday, September 1st. UBS AG raised their target price on shares of Baxter International from $57.00 to $62.00 and gave the stock a “neutral” rating in a research note on Friday, July 28th. Barclays PLC raised their target price on shares of Baxter International from $64.00 to $70.00 and gave the stock an “overweight” rating in a research note on Thursday, July 27th. BidaskClub cut shares of Baxter International from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Finally, Cowen and Company restated a “market perform” rating and set a $66.00 target price (up previously from $57.00) on shares of Baxter International in a research note on Monday, July 10th. One analyst has rated the stock with a sell rating, six have given a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus target price of $65.31.

Baxter International Profile

Baxter International Inc, through its subsidiaries, provides renal and hospital products. The Company operates through two segments: Hospital Products and Renal. Its Hospital Products business manufactures sterile intravenous (IV) solutions and administration sets, premixed drugs and drug-reconstitution systems, pre-filled vials and syringes for injectable drugs, IV nutrition products, parenteral nutrition therapies, infusion pumps, inhalation anesthetics and biosurgery products.

Want to see what other hedge funds are holding BAX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Baxter International Inc. (NYSE:BAX).

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply